Skip to main content
Thermo Fisher enters cancer NGS assay deal with Genome Canada, OICR

Thermo Fisher Scientific, Genome Canada and the Ontario Institute for Cancer Research signed a three-year agreement to develop three targeted next-generation sequencing-based assays and analysis software. Under the terms of the $4.5 million deal, assays for rapid diagnosis of pancreatic cancer and prostate and breast cancer treatment will be used to evaluate DNA and gene expression signatures for cancer driver mutations and for patient stratification in clinical studies.

Full Story: